Previous reports using pharmacological or genetic approaches to inhibit JMJD2A clearly highlighted that inhibition of JMJD2A enzymatic activity by small-molecule drugs may be effective in treating prostate cancer (12, 19, 20). This evidence concerns the gene KDM4A and prostate cancer.